Literature DB >> 17576391

Analysis of the relationship between cytokine secretion and proliferative capacity in hepatitis C virus infection.

N Semmo1, G Krashias, C Willberg, P Klenerman.   

Abstract

CD4(+) T-cell responses are important for the outcome of hepatitis C virus (HCV) infection. However, the functional status of HCV-specific CD4(+) T cells in persistent infection is poorly understood. It is generally recognized that proliferative capacity of HCV-specific CD4(+) T cells is weak or absent in persistent infection, but whether this results from deletion of antigen-specific cells or represents maintenance of antigen-specific but poorly proliferative populations is not defined. We used a set of ex vivo assays to evaluate the functionality of HCV specific CD4(+) T cells in persistent and resolved infection. Peripheral blood mononuclear cells (PBMC) from 24 prospectively recruited HCV polymerase chain reaction (PCR) positive individuals, 12 spontaneously resolved individuals (i.e. anti-HCV+, PCR-) and 11 healthy controls were analysed for interferon-gamma (IFN-gamma) and interleukin 2 (IL-2) secretion by enzyme linked immunospot assays (ELISpot). HCV-specific CD4(+) proliferative responses of carboxy fluorescein succinimidyl ester-labelled PBMC were assessed using a sensitive single cell flow cytometric assay. Sustained IFN-gamma ELISpot responses were observed in the PCR+ group. However, proliferation of HCV-specific CD4(+) T cells in the PCR+ group was substantially reduced on a per cell basis, in parallel to IL-2 secretion, compared with responses in the PCR- group. In PCR- individuals, a strong relationship between cytokine secretion and proliferative capacity was seen. However, in PCR+ individuals, IFN-gamma secretion far exceeded proliferative capacity. During persistent HCV infection, some CD4(+) T-cell specificities appear to be lost, as measured using a range of techniques, but others, potentially important, are maintained as IFN-gamma secretors but with low proliferative capacity even using a highly sensitive assay. Such subsets may yet play a significant role in vivo and also provide a template for modulation in immunotherapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17576391     DOI: 10.1111/j.1365-2893.2007.00842.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  12 in total

Review 1.  CD4+ T cell responses in hepatitis C virus infection.

Authors:  Nasser Semmo; Paul Klenerman
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

2.  Characterization of the specific CD4+ T cell response against the F protein during chronic hepatitis C virus infection.

Authors:  De-Yong Gao; Gen-Di Jin; Bi-Lian Yao; Dong-Hua Zhang; Lei-Lei Gu; Zhi-Meng Lu; Qiming Gong; Yu-Chun Lone; Qiang Deng; Xin-Xin Zhang
Journal:  PLoS One       Date:  2010-12-06       Impact factor: 3.240

3.  Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation.

Authors:  Eleonora Patsenker; Philip Sachse; Andrea Chicca; María Salomé Gachet; Vreni Schneider; Johan Mattsson; Christian Lanz; Mathias Worni; Andrea de Gottardi; Mariam Semmo; Jochen Hampe; Clemens Schafmayer; Rudolf Brenneisen; Jürg Gertsch; Felix Stickel; Nasser Semmo
Journal:  Int J Mol Sci       Date:  2015-03-27       Impact factor: 5.923

4.  Patient-derived hepatitis C virus inhibits CD4⁺ but not CD8⁺ T lymphocyte proliferation in primary T cells.

Authors:  Sonya A MacParland; Annie Y Chen; Christopher P Corkum; Tram N Q Pham; Tomasz I Michalak
Journal:  Virol J       Date:  2015-06-19       Impact factor: 4.099

5.  HCV genotype-3a T cell immunity: specificity, function and impact of therapy.

Authors:  Isla S Humphreys; Annette von Delft; Anthony Brown; Linda Hibbert; Jane D Collier; Graham R Foster; Monira Rahman; Annabel Christian; Paul Klenerman; Eleanor Barnes
Journal:  Gut       Date:  2012-02-15       Impact factor: 23.059

6.  Natural Killer Cells in Viral Hepatitis.

Authors:  Barbara Rehermann
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2015-11

7.  HCV core protein inhibits polarization and activity of both M1 and M2 macrophages through the TLR2 signaling pathway.

Authors:  Qianqian Zhang; Yang Wang; Naicui Zhai; Hongxiao Song; Haijun Li; Yang Yang; Tianyang Li; Xiaolin Guo; Baorong Chi; Junqi Niu; Ian Nicholas Crispe; Lishan Su; Zhengkun Tu
Journal:  Sci Rep       Date:  2016-10-27       Impact factor: 4.379

8.  A mutation in X-linked inhibitor of apoptosis (G466X) leads to memory inflation of Epstein-Barr virus-specific T cells.

Authors:  E Lopez-Granados; M Stacey; A-K Kienzler; S Sierro; C B Willberg; C P Fox; S Rigaud; H M Long; A D Hislop; A B Rickinson; S Patel; S Latour; P Klenerman; H Chapel
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

9.  Virological footprint of CD4+ T-cell responses during chronic hepatitis C virus infection.

Authors:  Vicki M Fleming; Gillian Harcourt; Eleanor Barnes; Paul Klenerman
Journal:  J Gen Virol       Date:  2010-01-27       Impact factor: 3.891

Review 10.  Methodologies for the Analysis of HCV-Specific CD4(+) T Cells.

Authors:  Megha U Lokhande; Robert Thimme; Paul Klenerman; Nasser Semmo
Journal:  Front Immunol       Date:  2015-02-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.